Marché des logiciels de dépistage du cancer du poumon en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2031

Analyse et taille du marché des logiciels de dépistage du cancer du poumon en Amérique du Nord

La détection et le diagnostic précoces sont une application majeure du marché des logiciels de dépistage du cancer du poumon. Ce logiciel s'appuie sur des algorithmes d'imagerie avancés pour analyser les tomodensitogrammes et autres images médicales, identifiant avec précision les nodules pulmonaires pouvant indiquer un cancer. En détectant ces nodules à un stade précoce, le logiciel permet un diagnostic et une intervention rapides, ce qui est essentiel pour améliorer les résultats des patients. Il réduit également les faux positifs et négatifs, garantissant ainsi que les patients reçoivent des soins de suivi appropriés. Cette capacité de détection précoce est essentielle pour augmenter les taux de survie et réduire le fardeau global du cancer du poumon.

La taille du marché des logiciels de dépistage du cancer du poumon en Amérique du Nord était évaluée à 24 415,25 milliers USD en 2023 et devrait atteindre 98 845,13 milliers USD d'ici 2031, avec un TCAC de 19,10 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Market Definition

Lung cancer screening software is a specialized tool designed to aid in the early detection and management of lung cancer. It facilitates the analysis of medical images, such as CT scans, to identify and monitor lung nodules. The software enhances the accuracy and efficiency of screening programs by integrating advanced imaging algorithms and patient management features.

Lung Cancer Screening Software Market Dynamics

Drivers                                                                                          

• Increasing Advancements in Imaging Technology

Improved imaging techniques, such as high-resolution CT scans and advanced image processing algorithms, enable more accurate and detailed visualization of lung tissues. These technological innovations allow for the early and precise detection of lung nodules, reducing false positives and negatives. As a result, healthcare providers can diagnose lung cancer at earlier stages, leading to better patient outcomes. The constant evolution of imaging technology ensures that screening software remains effective and reliable, encouraging its widespread adoption in clinical settings.

• Rising Incidence of Lung Cancer

Lung cancer rates continue to increase globally, due which there is a growing need for effective screening solutions to facilitate early detection and treatment. This heightened prevalence pushes healthcare providers to adopt advanced screening technologies to improve diagnostic accuracy and patient outcomes. Consequently, the demand for lung cancer screening software, which enhances the ability to detect and manage lung cancer at earlier stages, is on the rise, fueling market growth.

Opportunities

• Expansion of Government Initiatives

Many governments worldwide are implementing national and regional screening programs aimed at early detection and reduction of lung cancer mortality rates. These initiatives often include funding support, guidelines for screening protocols, and incentives for healthcare providers to adopt screening software. Governments also collaborate with healthcare organizations and research institutions to develop standardized screening practices and ensure quality control. By promoting awareness campaigns and public health policies focused on lung cancer prevention and early intervention, governments create a favorable environment for the adoption and expansion of lung cancer screening software, ultimately contributing to improved healthcare outcomes.

• Increasing Healthcare Expenditure

Expansion of healthcare budgets leads to greater investment in advanced diagnostic technologies and tools aimed at improving early detection and management of diseases such as lung cancer. This includes funding for the development and adoption of sophisticated imaging software that enhances accuracy in detecting lung nodules and potential cancers. Moreover, higher healthcare spending allows healthcare facilities to upgrade their infrastructure and equipment, facilitating the integration of state-of-the-art screening software into routine clinical practices. This trend supports the growth of the lung cancer screening software market by enabling wider access to advanced diagnostic capabilities and improving overall patient outcomes through timely intervention and treatment.

Restraints/Challenges

• High Cost of Implementation

Healthcare facilities face substantial expenses in acquiring the software itself, along with associated costs such as training healthcare professionals, upgrading infrastructure, and maintaining technical support. These financial barriers can be particularly challenging for smaller clinics or healthcare systems with limited budgets. Moreover, ongoing expenses related to software updates, compliance with regulatory standards, and data management further contribute to the overall cost burden.

• Increased Data Privacy Concerns

Lung cancer screening software solutions handle sensitive patient information which includes medical images and personal health data, there is heightened scrutiny over data security and privacy regulations such as HIPAA in the U.S. and GDPR in Europe. Healthcare providers and patients alike are increasingly concerned about the potential risks of data breaches and unauthorized access to confidential information. Compliance with stringent data protection laws requires substantial investment in secure infrastructure and adherence to strict protocols for data handling and storage, which can add complexity and cost to implementing screening software.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In July 2022, GE Healthcare launched the Voluson Expert 22, their most advanced ultrasound system to date. This new addition to their Women’s Health portfolio employs graphic-based beam former technology, resulting in higher quality imaging and greater flexibility in imaging functions. The introduction of this product significantly strengthened GE Healthcare’s position as a leading provider of products and services to healthcare institutions
• In October 2021, Thynk Health announced a collaboration with Infervision to combat lung cancer using cutting-edge technologies. This collaboration focuses on lung cancer screening and pulmonary nodule management, enhancing Thynk Health’s capabilities and market presence in the fight against lung cancer

Lung Cancer Screening Software Market Scope

The market is segmented on the basis of mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

• Cloud Based Solutions
• On-Premise Solutions
• Web Based Solutions

Product

• Lung Cancer Screening Radiology Solution
•  Lung Cancer Screening Patient Management Software
•  Nodule Management Software
•  Data Collection and Reporting
•  Patient Coordination and Workflow
•  Lung Nodule Computer Aided Detection
•  Pathology and Cancer Staging
•  Statistical Audit Reporting
•  Screening PACS
•  Practice Management
•  Audit Log Tracking

Type

• Computer-Assisted Screening
•  Traditional Screening

Application

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Platform

• Standalone
• Integrated

Purchase Mode

• Institutional
• Individual

End User

• Oncology Centers
• Hospitals
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Direct Tender
• Third Party Distributors

North America Lung Cancer Screening Software Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico.

U.S. dominate the market due to the implementation of numerous screening programs, the growing use of software solutions for patient management, and a rising demand for chest radiography screenings. Additionally, the presence of a large number of screening centers further strengthens the U.S.'s dominant position in this market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Lung Cancer Screening Software Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenetics diagnostic market.

Some of the major players operating in the market are:

• PenRad Technologies Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Volpara Health Limited (New Zealand)
• Thynk Health (U.S.)
• Nuance Communications, Inc. (U.S.)
• Siemens Healthcare GmbH (Germany)
• MyCareWare, Inc. (U.S.)
• MagView (U.S.)
• MeVis Medical Solutions AG (Allemagne)
• Canon Medical Informatics, Inc. (États-Unis)
• General Electric Company (États-Unis)
• Epic Systems Corporation (États-Unis)
• Lungview (États-Unis)
• Eon (États-Unis)
• Medtronic (Irlande)
• Coreline Soft Co., Ltd. (Corée du Sud)
• Optellum Ltd (Royaume-Uni)
• HealthMyne (États-Unis)
• Oncocyte Corporation (États-Unis)
• Genesystem (Corée du Sud)
• REVEALDX (États-Unis)
• FUJIFILM Holdings Corporation (Japon)
• F. Hoffmann-La Roche SA (Suisse)
• Median Technologies (France)
• AstraZeneca (Royaume-Uni)
• Aidence (Pays-Bas)

SKU-55134